Berkshire Capital Holdings Inc Crispr Therapeutics Ag Transaction History

Berkshire Capital Holdings Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$70.09 - $111.29 $700 - $1,112	-10 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$110.2 - $156.64 $6.27 Million - $8.91 Million	-56,910 Reduced 99.98%	10 $1,000
Q2 2021 Aug 13, 2021	BUY	$100.84 - $161.89 $5.74 Million - $9.21 Million	56,910 Added 569100.0%	56,920 $9.22 Million
Q1 2021 May 14, 2021	BUY	$110.72 - $210.04 $1,107 - $2,100	10 New	10 $1,000

491

58M

1.1M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.74B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Berkshire Capital Holdings Inc, based on Form 13F filings with the SEC.

Stay updated on Berkshire Capital Holdings Inc with notifications on news.